Interstitial Lung Disease

A review published in Chest highlights the need for a standardized method to identify and categorize patients’ environmental exposures to aid in the diagnosis and prevention of interstitial lung disease progression.

The FDA has approved subcutaneous tocilizumab to curb the rate of progressive loss of lung function among adults with systemic sclerosis-associated interstitial lung disease, according to a press release from Genentech.

Tocilizumab treatment in early interstitial lung disease, with progressive skin involvement related to systemic sclerosis, was able to stabilize forced vital capacity over 48 weeks, according to data published in Arthritis & Rheumatology.

The Healio editors have compiled a list of the most-read news on interstitial lung diseases published in 2020.

Statin therapy may have a significant benefit on progression of idiopathic pulmonary fibrosis, according to results of a retrospective study published in Respiratory Medicine.

In a new study, preexisting interstitial lung abnormalities were identified as risk factors for immune checkpoint inhibitor-induced interstitial lung disease in patients with nonlung cancers.

Mortality due to COVID-19 was higher in patients with preexisting fibrotic idiopathic interstitial lung disease compared with other interstitial lung diseases, researchers reported in a new study.

The need for anticoagulation in patients with interstitial lung disease is associated with an increased risk for death and transplant, according to findings published in Chest.

In this video, Jeffrey A. Sparks, MD, MMSc, associate physician at Brigham and Women's Hospital, offered take home messages from a study focused on rheumatoid arthritis-associated interstitial lung disease, or RA-ILD, presented at ACR 2020.

In this video, Jeffrey A. Sparks, MD, MMSc, associate physician at Brigham and Women's Hospital, explained the findings from his study that investigated the relationship between rheumatoid arthritis and pulmonary function.